Lung cancer and melanoma patients, particularly those in the advanced stages, can now explore a new option in treatment through a breakthrough called immunotherapy which has lesser known side effects than chemo. In serious cases of cancer, a protein found in the tumor called the Programmed Death-Ligand 1 (PD-L1) deactivates the immune system's T-cells so they become incapable of recognizing and destroying cancer cells. With immunotherapy, this interaction is blocked so that T-cells can detect and ward off the cancer cells. In a symposium on "The Future of ... Continue Reading...